How India Exports Actinomycin to the World

Actinomycin, known in the United States as dactinomycin, is an antineoplastic antibiotic used primarily in the treatment of various cancers. According to the FDA's Orange Book, there are several approved Abbreviated New Drug Applications (ANDAs) for dactinomycin, indicating the presence of generic versions in the market. The most recent approval was granted in June 2025. The regulatory pathway for dactinomycin involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug, without the need for extensive clinical trials.

Our proprietary trade data indicates that India exported actinomycin worth $2.9 million USD between 2022 and 2026, with 73.5% of these exports destined for the United States. This substantial export volume underscores the significance of the U.S. market for Indian manufacturers. Notably, EUGIA PHARMA SPECIALITIES LIMITED accounted for 61.4% of these exports, highlighting their dominant position in supplying actinomycin to the U.S.

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicinal products. Dactinomycin is authorized for use in the EU, with marketing authorizations granted to various pharmaceutical companies. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) continues to regulate dactinomycin post-Brexit, maintaining alignment with EU standards. Manufacturers exporting to these regions must comply with EU Good Manufacturing Practice (GMP) requirements, ensuring product quality and safety.

Dactinomycin is listed in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, signifying its importance in treating priority health conditions globally. Inclusion in this list guides countries in developing their national essential medicines lists. Additionally, dactinomycin is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, dactinomycin is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for dactinomycin, allowing market-driven pricing. For export purposes, manufacturers must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national regulations and monitoring of pharmaceutical exports.

The primary patents for dactinomycin have expired, leading to the availability of generic versions and increased competition in the market. This has facilitated the entry of multiple manufacturers, including Indian exporters, into international markets.

In August 2025, the NPPA announced a review of pricing policies for essential medicines, potentially impacting the pricing structure for drugs like dactinomycin. In October 2025, the EMA updated its guidelines on GMP compliance, emphasizing stricter quality control measures for oncology drugs, including dactinomycin. In December 2025, the WHO released the 24th edition of its Model List of Essential Medicines, reaffirming the inclusion of dactinomycin, which may influence national policies on its procurement and use.

These developments reflect the dynamic regulatory environment affecting the production, pricing, and distribution of dactinomycin, with implications for manufacturers and exporters.

India's pharmaceutical industry, including the production of Actinomycin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of APIs used in Indian pharmaceuticals are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance exposes the supply chain to risks associated with geopolitical tensions, trade disputes, and potential export restrictions.

The COVID-19 pandemic highlighted the vulnerabilities of this dependency, as disruptions in Chinese manufacturing led to shortages and price surges in essential drugs. In response, the Indian government initiated the Production Linked Incentive (PLI) scheme in October 2024 to bolster domestic production of critical APIs and KSMs, aiming to reduce import dependence by half. However, the effectiveness of these measures in achieving self-sufficiency remains to be fully realized.

Our proprietary trade data indicates that the top five exporters account for 81.1% of Actinomycin exports from India, with EUGIA PHARMA SPECIALITIES LIMITED alone contributing 61.4%. This high supplier concentration poses a significant risk, as any operational or compliance issues within these key companies could disrupt the entire supply chain.

The PLI scheme, launched in October 2024, aims to incentivize domestic production of critical APIs and KSMs. While this initiative is a step toward reducing dependency on imports and diversifying the supplier base, its impact on mitigating single-source risks in the Actinomycin supply chain is yet to be fully assessed.

Recent geopolitical tensions have significantly impacted global shipping routes critical to pharmaceutical supply chains. In February 2026, the closure of the Strait of Hormuz following attacks on Iran by the US and Israel disrupted the supply of raw materials to Asia's petrochemical industry, leading to production cutbacks and force majeure declarations. Additionally, escalating conflicts in the Red Sea region have heightened risks for commercial shipping, with potential implications for the timely delivery of pharmaceutical products.

While there have been no specific FDA or EMA shortage alerts for Actinomycin as of March 2026, the ongoing geopolitical instability underscores the need for proactive risk management strategies to ensure uninterrupted supply.

• Diversify Supplier Base: Engage with multiple suppliers across different regions to reduce dependency on a single source, thereby mitigating risks associated with supplier-specific disruptions.

• Enhance Domestic Production: Accelerate initiatives like the PLI scheme to strengthen domestic manufacturing capabilities for APIs and KSMs, reducing reliance on imports.

• Develop Alternative Shipping Routes: Identify and establish alternative logistics pathways to circumvent geopolitical hotspots, ensuring continuity in supply chains during regional conflicts.

• Implement Robust Inventory Management: Maintain strategic stockpiles of critical raw materials and finished products to buffer against supply chain disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to continuously assess geopolitical risks and their potential impact on the supply chain, enabling timely and informed decision-making.

RISK_LEVEL: HIGH